Factor XI Deficiency
- PMID: 34535287
- DOI: 10.1016/j.hoc.2021.07.012
Factor XI Deficiency
Abstract
Factor XI (FXI) deficiency (hemophilia C or Rosenthal disease) was first described in the 1950s in a multigenerational family experiencing bleeding related to surgery and dental procedures. Managing patients with FXI deficiency presents several challenges, including a lack of correlation of bleeding symptoms with FXI activity levels, the large volume of fresh frozen plasma required to achieve hemostatic FXI levels, lack of availability of FXI concentrate in certain regions of the world, and the inherent thrombotic risk associated with replacement therapy. This article summarizes presentation, diagnosis, and management of patients with FXI deficiency in a variety of clinical settings.
Keywords: Factor XI deficiency; Hemophilia C; Plasma thromboplastin antecedent deficiency; Rosenthal syndrome.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure M.D. Lewandowska: Advisory board for Bio Products Laboratory. All Honoraria donated to the Indiana Hemophilia and Thrombosis Center. J.M. Connors: No relationships to disclose related to this article; others include personal fees for scientific Ad Boards and Consulting: Abbott, Anthos, Alnylam, Bristol-Myers Squibb, Portola, and Takeda. Research funding to the institution from CSL Behring.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources